The purpose of this protocol is to treat an intermediate-sized population with chronic kidney disease (CKD) including kidney transplant recipients. The protocol uses allogeneic bone marrow-derived mesenchymal stem cells (MSCs). MSC infusion may be delivered 1) intravenous or 2) intravenous plus intra-arterial to both kidneys. Individuals will have subsequent follow up for safety evaluations. Repeat dosing is allowed.
Study Type
OBSERVATIONAL
Enrollment
75
1\) intravenous infusion or 2) combined intravenous plus intra-arterial (to kidney) infusion of cells. Total dose: 200x10\^6 MSC (administered over 15 minutes to 2 hours). Repeat dosing allowed at 6 month intervals.
Mayo Clinic
Jacksonville, Florida, United States
RECRUITINGAdverse events and/or serious adverse events
Number of adverse events and/or serious adverse events associated with mesenchymal stem cell (MSC) intervention
Time frame: 6 months after each MSC infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.